Your browser is no longer supported. Please, upgrade your browser.
GH Guardant Health, Inc. daily Stock Chart
Guardant Health, Inc.
Index- P/E- EPS (ttm)-6.16 Insider Own7.90% Shs Outstand87.83M Perf Week22.19%
Market Cap3.83B Forward P/E- EPS next Y-1.26 Insider Trans- Shs Float41.37M Perf Month18.45%
Income- PEG- EPS next Q-0.36 Inst Own21.90% Short Float2.57% Perf Quarter-
Sales67.21M P/S57.06 EPS this Y-92.90% Inst Trans- Short Ratio1.27 Perf Half Y-
Book/sh-18.83 P/B- EPS next Y- ROA- Target Price43.50 Perf Year-
Cash/sh3.09 P/C14.13 EPS next 5Y- ROE- 52W Range27.04 - 49.55 Perf YTD35.59%
Dividend- P/FCF- EPS past 5Y- ROI42.80% 52W High-11.89% Beta-
Dividend %- Quick Ratio9.00 Sales past 5Y- Gross Margin- 52W Low61.46% ATR3.73
Employees348 Current Ratio9.30 Sales Q/Q95.50% Oper. Margin- RSI (14)59.11 Volatility14.82% 9.01%
OptionableNo Debt/Eq- EPS Q/Q26.60% Profit Margin- Rel Volume0.38 Prev Close45.01
ShortableYes LT Debt/Eq- EarningsNov 19 AMC Payout- Avg Volume834.71K Price43.66
Recom1.80 SMA2012.33% SMA5019.61% SMA20019.61% Volume318,884 Change-3.00%
Oct-29-18Initiated William Blair Outperform
Oct-29-18Initiated JP Morgan Overweight $42
Oct-29-18Initiated BofA/Merrill Neutral $37
Dec-03-18 03:31PM  The Probable Reason Guardant Health Is Soaring Today Motley Fool +28.58%
Nov-26-18 02:03PM  Here's how much better insiders have profited from this year's IPO boom American City Business Journals
Nov-19-18 04:29PM  Guardant Health reports first earnings since IPO MarketWatch -9.74%
04:05PM  Guardant Health Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-13-18 04:03PM  Guardant Health To Report Third Quarter Financial Results on November 19, 2018 GlobeNewswire
Nov-01-18 02:51PM  Where SoftBanks Vision Fund is deploying its $100 billion Yahoo Finance
Oct-31-18 03:34PM  Strong IPO pace continued in October but some cracks are showing American City Business Journals
Oct-29-18 10:17AM  Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more American City Business Journals -6.86%
Oct-19-18 08:00AM  Guardant Health Presents Data on Immunotherapy-related Biomarkers MSI and TMB in blood of advanced cancer patients at European Society of Medical Oncology Annual Meeting PR Newswire -10.77%
Oct-16-18 08:00AM  Lung Cancer Study Published in JAMA Oncology Shows Guardant360 Outperforms Tissue Biopsy Alone in Identification of Targetable Mutations PR Newswire +13.04%
Oct-15-18 02:02PM  Unicorn births outpace IPOs in Bay Area: Here are the 24 new ones so far this year American City Business Journals
Oct-09-18 04:03PM  Guardant Health Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares GlobeNewswire +6.63%
Oct-05-18 08:00AM  Todays Research Reports on Stocks to Watch: Guardant Health and Vaxart ACCESSWIRE -9.32%
Oct-04-18 02:15PM  Nasdaq Welcomes Guardant Health, Inc. (Nasdaq: GH) to The Nasdaq Stock Market GlobeNewswire
11:01AM  Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early MarketWatch
10:55AM  Guardant Health's stock soars in public debut after IPO prices above expectations MarketWatch
09:02AM  Guardant Health IPO prices above expected range to value company at $1.6 billion MarketWatch
Oct-03-18 07:38PM  Guardant Health Announces Pricing of Initial Public Offering GlobeNewswire
Sep-30-18 09:41AM  IPO Outlook For The Week: Diagnostics, Data Miners And Freelance Facilitators Benzinga
Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.